Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland.
Flawless balance sheet with solid track record.
Share Price & News
How has Genomed Spólka Akcyjna's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GEN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GEN underperformed the Polish Biotechs industry which returned 60.4% over the past year.
Return vs Market: GEN exceeded the Polish Market which returned -19.4% over the past year.
Price Volatility Vs. Market
How volatile is Genomed Spólka Akcyjna's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StBoasting A 32% Return On Equity, Is Genomed Spólka Akcyjna (WSE:GEN) A Top Quality Stock?
1 year ago | Simply Wall StIs Genomed Spólka Akcyjna (WSE:GEN) Attractive At Its Current PE Ratio?
1 year ago | Simply Wall StIs Genomed Spólka Akcyjna's (WSE:GEN) 33.69% ROE Strong Compared To Its Industry?
Is Genomed Spólka Akcyjna undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GEN (PLN28.6) is trading above our estimate of fair value (PLN6.32)
Significantly Below Fair Value: GEN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GEN is poor value based on its PE Ratio (33.9x) compared to the Biotechs industry average (33.8x).
PE vs Market: GEN is poor value based on its PE Ratio (33.9x) compared to the Polish market (10.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GEN is good value based on its PB Ratio (5.3x) compared to the PL Biotechs industry average (5.3x).
How is Genomed Spólka Akcyjna forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genomed Spólka Akcyjna has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Check out Genomed Spólka Akcyjna's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
- Genomed Spólka Akcyjna competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Genomed Spólka Akcyjna performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GEN has high quality earnings.
Growing Profit Margin: GEN's current net profit margins (5.7%) are higher than last year (3.5%).
Past Earnings Growth Analysis
Earnings Trend: GEN has become profitable over the past 5 years, growing earnings by 34.2% per year.
Accelerating Growth: GEN's earnings growth over the past year (70.3%) exceeds its 5-year average (34.2% per year).
Earnings vs Industry: GEN earnings growth over the past year (70.3%) exceeded the Biotechs industry 17.1%.
Return on Equity
High ROE: GEN's Return on Equity (15.7%) is considered low.
How is Genomed Spólka Akcyjna's financial position?
Financial Position Analysis
Short Term Liabilities: GEN's short term assets (PLN6.2M) exceed its short term liabilities (PLN1.2M).
Long Term Liabilities: GEN's short term assets (PLN6.2M) exceed its long term liabilities (PLN176.7K).
Debt to Equity History and Analysis
Debt Level: GEN is debt free.
Reducing Debt: GEN has not had any debt for past 5 years.
Debt Coverage: GEN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GEN has no debt, therefore coverage of interest payments is not a concern.
What is Genomed Spólka Akcyjna's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GEN's dividend (3.5%) is higher than the bottom 25% of dividend payers in the Polish market (2.24%).
High Dividend: GEN's dividend (3.5%) is low compared to the top 25% of dividend payers in the Polish market (6.95%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether GEN's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if GEN's dividend payments are increasing as they only just started paying a dividend.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (118.6%), GEN's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Dr. Hab. Anna Boguszewska-Chachulska, Ph.D. is a Co-founder of Genomed Spólka Akcyjna and has been its Chief Executive Officer since 2013. Dr. Hab. Boguszewska-Chachulska also serves as President of the Ma ...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Genomed Spólka Akcyjna's company bio, employee growth, exchange listings and data sources
- Name: Genomed Spólka Akcyjna
- Ticker: GEN
- Exchange: WSE
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: zł37.789m
- Shares outstanding: 1.32m
- Website: https://www.genomed.pl
- Genomed Spólka Akcyjna
- ul. Ponczowa 12
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GEN||WSE (Warsaw Stock Exchange)||Yes||Bearer Shares||PL||PLN||May 2011|
Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers analysis of mutations responsible for congenital diseases in approximately 120 genes; and next generation sequencing technology. In addition, it provides various types of DNA sequence analysis, including polymorphism analysis, and the sequencing of phage genetic material, or bacteria and yeast genomes; and next generation sequencing and genetic counseling services. Further, the company offers DNA oligonucleotides synthesis, RNA oligonucleotides and peptide synthesis, various nucleotide modifications, and the 4LAB automated pipetting workstation, as well as laboratory equipment through the eStore. It serves scientific institutes, universities, hospitals, and biotechnological and pharmaceutical companies, as well as healthcare networks and individual customers. Genomed Spólka Akcyjna is based in Warsaw, Poland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/01 23:44|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.